PPARGC1A and neoplasm: Various small-molecule inhibitors have been developed to target key regulators involved in tumor mitochondrial biogenesis, including PGC-1α, PGC-1β, the estrogen-related receptor family (ERRs), and estrogen receptor alpha (ERα) [63].